Physician profile
Cara Debusk
NPI 1790015600
$4,392.95
in general payments reported to CMS, 2019-2025
23 companies · $831 in 2025
The $831 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,132 · 2022: $647 · 2023: $930 · 2024: $853 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516 · Education: $98.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.36 |
| Education | $98.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,754.15 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Csl Behring | $560.54 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $292.93 | 2021-2025 | Dupixent |
| Octapharma USA, INC. | $199.06 | 2021-2023 | Cutaquig |
| Astrazeneca Pharmaceuticals LP | $198.33 | 2021-2025 | Tezspire |
| Genzyme Corporation | $175.84 | 2022-2024 | |
| Pfizer INC. | $172.11 | 2021-2025 | |
| Genentech USA, INC. | $157.40 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $153.79 | 2021-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $143.03 | 2021-2025 | |
| Grifols USA, LLC | $120.79 | 2021-2024 | Xembify |
| Adma Biomanufacturing LLC | $84.80 | 2021-2022 | |
| Coloplast Corp | $80.58 | 2022 | |
| Pharming Healthcare, INC. | $76.66 | 2022-2023 | Ruconest |
| Ionis Pharmaceuticals, INC. | $38.91 | 2025 | Dawnzera |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.50 | 2024 | Ebglyss |
| Blueprint Medicines Corporation | $26.64 | 2025 | Ayvakit |
| X4 Pharmaceuticals, INC. | $24.67 | 2024 | Xolremdi |
| Ars Pharmaceuticals Operations, INC. | $24.49 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $21.57 | 2021 | |
| Kaleo, INC. | $19.95 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.02 | 2021 | |
| Alk-Abello, INC | $16.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Debusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.